Biotechnology

Athenex is constructing a $210 million pharmaceutical plant in Dunkirk, N.Y. Supporting the production of advanced cancer therapies, the 409,000-sf complex will provide research, office, manufacturing, and warehouse space. General contractor Exyte broke ground on the facility in May of 2018, and commercial operations will commence at the site in early 2022. The project is part of a strategic infrastructure development plan to enable Athenex to offer vertically integrated oncology services from discovery through marketing.

Merck KGaA broke ground in early 2020 on the $275 Biotech Development Center in Corsier-sur-Vevey, Switzerland. Constructed adjacent to the company's existing commercial manufacturing campus, the 169,000-sf project will provide advanced research, development, and production facilities to support the creation of innovative biological compounds for clinical studies.

Foghorn Therapeutics broke ground in January of 2020 on its 60,000-sf headquarters in Cambridge, Mass. Located in Kendall Square, the facility will provide chemistry and biology labs, open offices, conference rooms, huddle rooms, and an employee café. Foghorn will occupy over three floors in the building, which is owned by Alexandria Real Estate Equities and managed by CBRE.

St. Jude's Children's Research Hospital is constructing the $13.4 million Shared Resource Center in Memphis, Tenn. Accommodating 60 employees, the project will provide core laboratories and instrumentation suites to accelerate the discovery of new treatments for pediatric cancer and other diseases. Created inside an existing 300,000-sf warehouse, the 100,000-sf center will house: 

The University of California, Davis has selected Wexford Science + Technology and GMH Capital Partners to develop the first phase of Aggie Square in Sacramento. The two firms will finance, design, construct, and own the facilities, which will include 250,000 sf of classroom and co-working space, 500,000 sf of engineering, science, and technology space, 30,000 sf of ground-floor public space, and approximately 200 housing units.

HALIX opened a 72,000-sf biopharmaceutical development and manufacturing center in November of 2019 at Leiden Bio Science Park in the Netherlands. The five-story structure provides BSL-2 cleanrooms with unidirectional process flows that can easily be upgraded to BSL-3 as needed. A manufacturing line with a 250-liter bioreactor capacity supports the production of viral vaccines and viral vectors, while a separate protein manufacturing area accommodates single-use bioreactors with a capacity of up to 1,000 liters.

Thermo Fisher Scientific opened a $90 million viral vector facility in December of 2019 in Lexington, Mass. Featuring specialized GMP laboratories, the 50,000-sf project will accommodate the development, testing, and manufacture of viral vectors for the creation of gene and cell therapies. The center will act as a CDMO (contract development and manufacturing organization) site and will offer services including from drug development through clinical trials and commercial production.

Florida Atlantic University hosted a ceremonial groundbreaking for its $35 million Neuroscience Building in Jupiter in November of 2019. Construction will begin in summer of 2020 on the facility, which will provide shared research labs, faculty offices, a business incubator, and instructional space for programs in neuroscience, biotechnology, bioengineering, bioinformatics, and chemistry. The 58,000-sf project is strategically sited on the John D.

AZI is constructing an 85,000-sf isoptope production and research facility in Bunker Hill, Ind. The $44.5 million project includes the expansion of a 55,000-sf shell building by 30,000 sf to accommodate a 280,000-pound 70MeV cyclotron. The existing structure was purchased at a cost of $2.8 million. AZI (Arizona Isotopes Science Research Corp.) is based in Phoenix and supplies medical isotopes to companies and institutions worldwide. The facility is strategically sited near the Grissom Aeroplex, a public and military airport with a 12,500-sf runway.

Grand River Aseptic Manufacturing (GRAM) is constructing a $60 million facility in Grand Rapids, Mich. Designed by CRB, the 61,500-sf facility will include a state-of-the-art cleanroom, two formulation suites, and 14,000 sf of shell space to accommodate future growth. Capable of producing a wide range of commercial batch sizes, the aseptic manufacturing plant will integrate leading-edge automation technologies and high-speed instrumentation to support the production of parenteral medicinal solutions.

Beacon Pharmaceuticals is planning to break ground by early 2020 on a 150,000-sf biosciences accelerator and headquarters facility in Jupiter, Fla. Designed by Kobi Karp Architecture & Interior Design, the $80 million facility will feature a pharmaceutical business incubator to support early-stage companies from concept to commercialization.

North Carolina State University broke ground on the $160 million Plant Sciences Building in Raleigh in September of 2019. Designed by Flad Architects, the five-story, 184,000-sf facility will allow academic, government, and industry researchers to develop innovative solutions for global agricultural challenges. Located on the Centennial Campus, the building will house growth chambers, environmental rooms, core instrumentation suites, and labs for genotyping, spectrometry, ag-bio engineering, and chemical and soils analysis.

Pfizer is initiating a $500 million expansion of its Sanford campus with the construction of a 100,000-sf gene therapy facility. Supporting the creation of innovative treatments for genetic diseases, the project will feature advance manufacturing technologies for clinical and commercial-scale production of recombinant adeno-associated virus (rAAV) vectors. Accommodating 300 new employees, the facility will complement operations at the existing 628,000-sf Sanford complex and at the company's Chapel Hill and Kit Creek locations.

Amgen broke ground in late July of 2019 on a $200 million biomanufacturing center in West Greenwich, R.I. Featuring a highly flexible, modular design, the next-generation facility will leverage advanced technologies to reduce operational expenses, consume 80 percent less energy and water, and achieve a 75 percent decrease in carbon emissions.

DLJ Real Estate Capital Partners and Leggat McCall Properties are building a Class-A laboratory building in Somerville, Mass. The nine-story, 289,000-sf facility will provide leading-edge research and office space for life sciences and technology companies. The mixed-use development will include dedicated retail space on the ground floor and four levels of underground parking.